← FDA DRUG APPROVALS

FDA NDA · NDA018885

EMBOLEX

Sponsor: NOVARTIS

APPLICATION
NDA018885
TYPE
NDA
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

EMBOLEXDiscontinued
DIHYDROERGOTAMINE MESYLATE 0.5MG/0.7ML, HEPARIN SODIUM 5,000 UNITS/0.7ML, LIDOCAINE HYDROCHLORIDE 7.46MG/0.7ML · INJECTABLE · INJECTION
EMBOLEXDiscontinued
DIHYDROERGOTAMINE MESYLATE 0.5MG/0.5ML, HEPARIN SODIUM 2,500 UNITS/0.5ML, LIDOCAINE HYDROCHLORIDE 5.33MG/0.5ML · INJECTABLE · INJECTION
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →